These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

639 related items for PubMed ID: 8996185

  • 21. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
    Park WK, Jeong D, Cho H, Lee SJ, Cha MY, Pae AN, Choi KI, Koh HY, Kong JY.
    Pharmacol Biochem Behav; 2005 Oct; 82(2):361-72. PubMed ID: 16216322
    [Abstract] [Full Text] [Related]

  • 22. S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: III. Actions in models of therapeutic activity and induction of side effects.
    Millan MJ, Loiseau F, Dekeyne A, Gobert A, Flik G, Cremers TI, Rivet JM, Sicard D, Billiras R, Brocco M.
    J Pharmacol Exp Ther; 2008 Mar; 324(3):1212-26. PubMed ID: 18096759
    [Abstract] [Full Text] [Related]

  • 23. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.
    Grundt P, Carlson EE, Cao J, Bennett CJ, McElveen E, Taylor M, Luedtke RR, Newman AH.
    J Med Chem; 2005 Feb 10; 48(3):839-48. PubMed ID: 15689168
    [Abstract] [Full Text] [Related]

  • 24. CI-1007, a dopamine partial agonist and potential antipsychotic agent. I. Neurochemical effects.
    Rugsley TA, Davis MD, Akunne HC, Cooke LW, Whetzel SZ, MacKenzie RG, Shih YH, van Leeuwen DH, DeMattos SB, Georgic LM.
    J Pharmacol Exp Ther; 1995 Aug 10; 274(2):898-911. PubMed ID: 7636753
    [Abstract] [Full Text] [Related]

  • 25. D2 receptor occupancy in conscious rat brain is not significantly distinguished with [3H]-MNPA, [3H]-(+)-PHNO, and [3H]-raclopride.
    Peng T, Zysk J, Dorff P, Elmore CS, Ström P, Malmquist J, Ding M, Tuke D, Werkheiser J, Widzowski D, Mrzljak L, Maier D.
    Synapse; 2010 Aug 10; 64(8):624-33. PubMed ID: 20340171
    [Abstract] [Full Text] [Related]

  • 26. In vitro receptor binding characteristics of the new dopamine D2 antagonist [125I]NCQ-298: methodological considerations of high affinity binding.
    Jerning E, Malmberg A, Mohell N.
    J Recept Signal Transduct Res; 1995 Aug 10; 15(1-4):503-15. PubMed ID: 8903960
    [Abstract] [Full Text] [Related]

  • 27. Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A.
    Reavill C, Taylor SG, Wood MD, Ashmeade T, Austin NE, Avenell KY, Boyfield I, Branch CL, Cilia J, Coldwell MC, Hadley MS, Hunter AJ, Jeffrey P, Jewitt F, Johnson CN, Jones DN, Medhurst AD, Middlemiss DN, Nash DJ, Riley GJ, Routledge C, Stemp G, Thewlis KM, Trail B, Vong AK, Hagan JJ.
    J Pharmacol Exp Ther; 2000 Sep 10; 294(3):1154-65. PubMed ID: 10945872
    [Abstract] [Full Text] [Related]

  • 28. [35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents.
    Newman-Tancredi A, Audinot V, Chaput C, Verrièle L, Millan MJ.
    J Pharmacol Exp Ther; 1997 Jul 10; 282(1):181-91. PubMed ID: 9223553
    [Abstract] [Full Text] [Related]

  • 29. [Functional role of dopamine D3 receptor in schizophrenia].
    Semba J.
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2004 Feb 10; 24(1):3-11. PubMed ID: 15027325
    [Abstract] [Full Text] [Related]

  • 30. Ex vivo studies with iloperidone (HP 873), a potential atypical antipsychotic with dopamine D2/5-hydroxytryptamine2 receptor antagonist activity.
    Szczepanik AM, Brougham LR, Roehr JE, Conway PG, Ellis DB, Wilmot CA.
    J Pharmacol Exp Ther; 1996 Aug 10; 278(2):913-20. PubMed ID: 8768747
    [Abstract] [Full Text] [Related]

  • 31. [3H]-quinelorane binds to D2 and D3 dopamine receptors in the rat brain.
    Gackenheimer SL, Schaus JM, Gehlert DR.
    J Pharmacol Exp Ther; 1995 Sep 10; 274(3):1558-65. PubMed ID: 7562534
    [Abstract] [Full Text] [Related]

  • 32. Amisulpride the 'atypical' atypical antipsychotic--comparison to haloperidol, risperidone and clozapine.
    Natesan S, Reckless GE, Barlow KB, Nobrega JN, Kapur S.
    Schizophr Res; 2008 Oct 10; 105(1-3):224-35. PubMed ID: 18710798
    [Abstract] [Full Text] [Related]

  • 33. Zinc modulates antagonist interactions with D2-like dopamine receptors through distinct molecular mechanisms.
    Schetz JA, Chu A, Sibley DR.
    J Pharmacol Exp Ther; 1999 May 10; 289(2):956-64. PubMed ID: 10215675
    [Abstract] [Full Text] [Related]

  • 34. Biochemical profile of risperidone, a new antipsychotic.
    Leysen JE, Gommeren W, Eens A, de Chaffoy de Courcelles D, Stoof JC, Janssen PA.
    J Pharmacol Exp Ther; 1988 Nov 10; 247(2):661-70. PubMed ID: 2460616
    [Abstract] [Full Text] [Related]

  • 35. A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers.
    Rosenzweig P, Canal M, Patat A, Bergougnan L, Zieleniuk I, Bianchetti G.
    Hum Psychopharmacol; 2002 Jan 10; 17(1):1-13. PubMed ID: 12404702
    [Abstract] [Full Text] [Related]

  • 36. Dopamine D3 and D4 receptor antagonists: synthesis and structure--activity relationships of (S)-(+)-N-(1-Benzyl-3-pyrrolidinyl)-5-chloro-4- [(cyclopropylcarbonyl) amino]-2-methoxybenzamide (YM-43611) and related compounds.
    Ohmori J, Maeno K, Hidaka K, Nakato K, Matsumoto M, Tada S, Hattori H, Sakamoto S, Tsukamoto S, Usuda S, Mase T.
    J Med Chem; 1996 Jul 05; 39(14):2764-72. PubMed ID: 8709107
    [Abstract] [Full Text] [Related]

  • 37. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors.
    Millan MJ, Mannoury la Cour C, Novi F, Maggio R, Audinot V, Newman-Tancredi A, Cussac D, Pasteau V, Boutin JA, Dubuffet T, Lavielle G.
    J Pharmacol Exp Ther; 2008 Feb 05; 324(2):587-99. PubMed ID: 18024789
    [Abstract] [Full Text] [Related]

  • 38. Antagonism of the discriminative stimulus effects of cocaine at two training doses by dopamine D2-like receptor antagonists.
    Costanza RM, Barber DJ, Terry P.
    Psychopharmacology (Berl); 2001 Nov 05; 158(2):146-53. PubMed ID: 11702088
    [Abstract] [Full Text] [Related]

  • 39. Unique binding characteristics of antipsychotic agents interacting with human dopamine D2A, D2B, and D3 receptors.
    Malmberg A, Jackson DM, Eriksson A, Mohell N.
    Mol Pharmacol; 1993 May 05; 43(5):749-54. PubMed ID: 8099194
    [Abstract] [Full Text] [Related]

  • 40. Quinpirole-induced 50 kHz ultrasonic vocalization in the rat: role of D2 and D3 dopamine receptors.
    Brudzynski SM, Komadoski M, St Pierre J.
    Behav Brain Res; 2012 Jan 15; 226(2):511-8. PubMed ID: 22015714
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 32.